In Malaysia, drug safety is evaluated by the National Pharmaceutical Regulatory Agency (NPRA) through a rigorous process involving pre-clinical and clinical trials, assessment of manufacturing practices, and post-marketing surveillance. The evaluation ensures compliance with international standards, focusing on efficacy, quality, and safety... Read More
In Malaysia, drug labeling requirements are enforced by the National Pharmaceutical Regulatory Agency (NPRA) under the Ministry of Health. The NPRA ensures compliance through stringent regulations, regular inspections, and mandatory product registration. Non-compliance can result in penalties, product recalls, or suspension of... Read More
The ASEAN Common Technical Dossier (ACTD) streamlines drug registration in Malaysia by standardizing documentation requirements across ASEAN member states. It facilitates efficient evaluation and approval processes, ensuring consistent quality, safety, and efficacy of pharmaceuticals. This harmonization reduces administrative burdens, accelerates market access,... Read More
Yes, orphan drugs in Malaysia are eligible for special registration pathways. The National Pharmaceutical Regulatory Agency (NPRA) offers expedited review processes to facilitate faster access to these drugs, addressing rare diseases with unmet medical needs. This approach aims to encourage the development... Read More
Malaysia handles the registration of combination products through the National Pharmaceutical Regulatory Agency (NPRA). Applicants must submit a single application, specifying the primary mode of action. The NPRA evaluates safety, efficacy, and quality, coordinating with relevant agencies to ensure compliance with pharmaceutical... Read More
In Malaysia, the timeline for reviewing a drug registration application typically ranges from 210 to 245 working days. This period includes the initial screening, evaluation, and decision-making phases. The process may vary depending on the drug’s classification and the completeness of the... Read More
In Malaysia, selling unregistered drugs is a serious offense under the Sale of Drugs Act 1952. Penalties include fines up to RM25,000 and/or imprisonment up to three years for first-time offenders. Repeat offenders face fines up to RM50,000 and/or imprisonment up to... Read More
In Malaysia, updates to registered drugs are managed by the National Pharmaceutical Regulatory Agency (NPRA). Manufacturers must submit variation applications detailing changes. The NPRA evaluates these for safety, efficacy, and quality. Approved updates are reflected in the product registration, ensuring compliance with... Read More
Yes, Malaysia offers expedited registration pathways for certain drugs through the Conditional Registration Pathway and Priority Review Scheme. These pathways are designed to accelerate the approval process for drugs addressing unmet medical needs, serious conditions, or public health emergencies, ensuring timely access... Read More
To renew a drug registration in Malaysia, submit a renewal application via the National Pharmaceutical Regulatory Agency’s QUEST system. Ensure all required documents, including updated product information and fees, are included. The application should be submitted at least six months before expiration.... Read More